Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Porphozym for Acute Attacks in AIP
NCT00418795Phase 3Completed
- Sponsor
- Zymenex
- Start
- Jun 2003
- Primary completion
- Jun 2006
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human porphobilinogen deaminase in acute intermittent porphyria (AIP), sponsored by Zymenex. Started Jun 2003; status: completed.
02
Drugs
recombinant human porphobilinogen deaminase
03
Conditions
acute intermittent porphyria (AIP)
Beyond the preview
Go deeper on NCT00418795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00418795.